Silicified Microcrystalline Cellulose | Pharma Excipients | News | Suppliers

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Virtual Booth

Contact Supplier

Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

CHEMISTRY

Browse all information

INACTIVE PHARMA INGREDIENTS

57 Suppliers, 56 USDMF, 5 CEP/COS, 39 Listed Suppliers

57 Suppliers
56 USDMF
5 CEP/COS
39 Listed Suppliers

FINISHED DOSAGE FORMULATIONS

3243 FDF Dossiers Suppliers

3243 FDF Dossiers Suppliers

EXCIPIENTS BY APPLICATIONS

19 Fillers, Diluents & Binders, 10 Co-Processed Excipients, 8 Direct Compression, 7 Thickeners and Stabilizers, 5 Granulation, 4 Disintegrants & Superdisintegrants, 3 Controlled & Modified Release, 2 Chewable & Orodispersible Aids, 2 Taste Masking, 2 Coating Systems & Additives, 1 Rheology Modifiers, 1 Film Formers & Plasticizers, 1 Lubricants & Glidants

19 Fillers, Diluents & Binders
10 Co-Processed Excipients
8 Direct Compression
7 Thickeners and Stabilizers
5 Granulation
4 Disintegrants & Superdisintegrants
3 Controlled & Modified Release
2 Chewable & Orodispersible Aids
2 Taste Masking
2 Coating Systems & Additives
1 Rheology Modifiers
1 Film Formers & Plasticizers
1 Lubricants & Glidants

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 3 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
3 NEWS #PharmaBuzz

MARKET PLACE

2 APIs, 32 EXCIPIENTS

2 APIs
32 EXCIPIENTS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

SUPPLIERS

01

M B Sugars & Pharmaceuticals Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Indo Livestock Expo

Not Confirmed

02

Sigachi Industries

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Indo Livestock Expo

Not Confirmed

03

Sigachi Industries

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Indo Livestock Expo

Not Confirmed

04

Sigachi Industries

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Indo Livestock Expo

Not Confirmed

05

Mingtai Chemical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Indo Livestock Expo

Not Confirmed

06

Mingtai Chemical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Indo Livestock Expo

Not Confirmed

07

Mingtai Chemical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Indo Livestock Expo

Not Confirmed

08

Mingtai Chemical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Indo Livestock Expo

Not Confirmed

09

Kerry

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Indo Livestock Expo

Not Confirmed

10

Kerry

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Indo Livestock Expo

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

Asahi Kasei Corp

Japan

EPS

Not Confirmed

02

International Flavors And Fragrances...

U.S.A

EPS

Not Confirmed

03

International Flavors And Fragrances...

U.S.A

EPS

Not Confirmed

04

International N&h Usa Inc

U.S.A

EPS

Not Confirmed

05

Jrs Pharma Lp

Germany

EPS

Not Confirmed

06

Jrs Pharma Lp

Germany

EPS

Not Confirmed

07

Jrs Pharma Lp

Germany

EPS

Not Confirmed

08

Jrs Pharma Gmbh And Co Kg

Germany

EPS

Not Confirmed

09

Jrs Pharma Gmbh And Co Kg

Germany

EPS

Not Confirmed

10

Itacel Farmoquimica Ltda

France

EPS

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

01

JRS Pharma GmbH & Co. KG. Rosenberg...

Germany

EPS

Not Confirmed

02

Mingtai Chemical Co., Ltd. Taoyuan ...

China

EPS

Not Confirmed

03

RANQ REMEDIES PVT. LTD. Kurkumbh IN

India

EPS

Not Confirmed

04

SIGACHI INDUSTRIES LIMITED Hyderaba...

India

EPS

Not Confirmed

05

INTERNATIONAL N&H USA, INC Newark U...

Country

EPS

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FINISHED DOSAGE FORMULATIONS

Upload your portfolio for free, ask us

FDF DOSSIERS SUPPLIERS

01

SANOFI

France

ChemOutsourcing

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

TAMSULOSIN HYDROCHLORIDE

Drug : FLOMAX

Dosage Form : CAPSULE; ORAL

Application Number : 20579

Country : US

Patented : No

Portfolio PDF

Product Web Link

02

SANOFI

France

ChemOutsourcing

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

SEVELAMER CARBONATE

Drug : RENVELA

Dosage Form : TABLET; ORAL

Application Number : 22127

Country : US

Patented : Yes

Portfolio PDF

Product Web Link

03

SANOFI AVENTIS US

France

ChemOutsourcing

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

GLIMEPIRIDE

Drug : AMARYL

Dosage Form : TABLET; ORAL

Application Number : 20496

Country : US

Patented : No

Portfolio PDF

Product Web Link

04

SANOFI AVENTIS US

France

ChemOutsourcing

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

TELITHROMYCIN

Drug : KETEK

Dosage Form : TABLET; ORAL

Application Number : 21144

Country : US

Patented : No

Portfolio PDF

Product Web Link

05

SANOFI AVENTIS US

France

ChemOutsourcing

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

GLYBURIDE

Drug : DIABETA

Dosage Form : TABLET; ORAL

Application Number : 17532

Country : US

Patented : No

Portfolio PDF

Product Web Link

06

SANOFI AVENTIS US

France

ChemOutsourcing

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

RIFAPENTINE

Drug : PRIFTIN

Dosage Form : TABLET; ORAL

Application Number : 21024

Country : US

Patented : No

Portfolio PDF

Product Web Link

07

SANOFI AVENTIS US

France

ChemOutsourcing

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

MEPENZOLATE BROMIDE

Drug : CANTIL

Dosage Form : SOLUTION; ORAL

Application Number : 10679

Country : US

Patented : No

Portfolio PDF

Product Web Link

08

SANOFI AVENTIS US

France

ChemOutsourcing

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

CLOPIDOGREL BISULFATE

Drug : PLAVIX

Dosage Form : TABLET; ORAL

Application Number : 20839

Country : US

Patented : No

Portfolio PDF

Product Web Link

09

SANOFI AVENTIS US

France

ChemOutsourcing

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

MEPENZOLATE BROMIDE

Drug : CANTIL

Dosage Form : TABLET; ORAL

Application Number : 10679

Country : US

Patented : No

Portfolio PDF

Product Web Link

10

SANOFI AVENTIS US

France

ChemOutsourcing

Attending

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

HYDROCHLOROTHIAZIDE; IRBESARTAN

Drug : AVALIDE

Dosage Form : TABLET; ORAL

Application Number : 20758

Country : US

Patented : No

Portfolio PDF

Product Web Link

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EXCIPIENTS BY APPLICATIONS

Click here to find the perfect excipient manufacturers by their capabilities

Fillers Diluents Binders

01

Gangwal Healthcare

India

CPhI South East Asia

Attending

Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

Dosage Form : Capsule, Tablet

Grade : Oral

Category : Fillers, Diluents & Binders

Brand Name : ProBlend®

Application : Fillers, Diluents & Binders

Excipient Details : ProBlend (SMCC) is a co-processed excipient consists of microcrystalline cellulose & colloidal silicon dioxide, used as a diluent & binder in OSDs.

Pharmacopoeia Ref : USP-NF, DMF, EXCiPAT, KOSHER, ...

Technical Specs : NA

Ingredient(s) : Silicified Microcrystalline Cellulose

02

Gangwal Healthcare

India

CPhI South East Asia

Attending

Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

Dosage Form : Tablet

Grade : Oral

Category : Fillers, Diluents & Binders

Brand Name : Microlose™

Application : Fillers, Diluents & Binders

Excipient Details : Microlose (Lactose Monohydrate & Microcrystalline Cellulose) is used as a diluent in oral dosage forms such as tablets.

Pharmacopoeia Ref : DMF, EXCiPAT, KOSHER, HALAL, W...

Technical Specs : Lactose Monohydrate – 40%, Microcrystalline cellulose – 60%

Ingredient(s) : Microcrystalline Cellulose

03

Nitika Pharmaceutical Specialities

India

Indo Livestock Expo

Not Confirmed

04

Keval Exports

India

Indo Livestock Expo

Not Confirmed

05

Sigachi Industries

India

Indo Livestock Expo

Not Confirmed

06

Shanghai Shenmei Pharmaceutical Te...

China

Indo Livestock Expo

Not Confirmed

07

Vasa Pharmachem

India

Indo Livestock Expo

Not Confirmed

08

Prachin Chemical

India

Indo Livestock Expo

Not Confirmed

09

Sigachi Industries

India

Indo Livestock Expo

Not Confirmed

10

Silverline Chemicals

India

Indo Livestock Expo

Not Confirmed

Only 10 entries up to this point, click to access all

Co Processed Excipients

Direct Compression

01

DFE Pharma

Germany

Pharmex

Not Confirmed

02

Sigachi Industries

India

Pharmex

Not Confirmed

03

Sigachi Industries

India

Pharmex

Not Confirmed

04

Sigachi Industries

India

Pharmex

Not Confirmed

05

Sigachi Industries

India

Pharmex

Not Confirmed

06

Microlex e.U

Austria

Pharmex

Not Confirmed

07

Microlex e.U

Austria

Pharmex

Not Confirmed

08

Sigachi Industries

India

Pharmex

Not Confirmed

Thickeners And Stabilizers

Granulation

Disintegrants Superdisintegrants

01

Anhui Sunhere Pharmaceutical Excip...

China

Pharmex

Not Confirmed

02

Sigachi Industries

India

Pharmex

Not Confirmed

03

Gangwal Chemicals

India

Pharmex

Not Confirmed

04

Gangwal Chemicals

India

Pharmex

Not Confirmed

Controlled Modified Release

Chewable Orodispersible Aids

Taste Masking

01

Sigachi Industries

India

EPS

Not Confirmed

02

Gangwal Chemicals

India

EPS

Not Confirmed

Coating Systems Additives

01

SPI Pharma

U.S.A

World Vaccine Congress

Attending

SPI Pharma has been solving formulation challenges using superior functional materials.

Dosage Form : Tablet

Grade : Oral

Category : Coating Systems & Additives

Brand Name : ACTILLETS™

Application : Coating Systems & Additives

Excipient Details : ACTILLETS are microcrystalline cellulose spheres developed using advanced drug delivery technology to enable effective loading & coating of particles.

Pharmacopoeia Ref : NA

Technical Specs : Not Available

Ingredient(s) : Microcrystalline Cellulose

02

Gangwal Chemicals

India

EPS

Not Confirmed

Rheology Modifiers

Film Formers Plasticizers

Lubricants Glidants

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards. Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio. Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients. The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.